Vera Therapeutics VERA EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Vera Therapeutics’s reported figures.
The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vera Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vera Therapeutics's EBITDA?
- Vera Therapeutics (VERA) reported EBITDA of -$124.99M in Q1 2026.
- How has Vera Therapeutics's EBITDA changed year-over-year?
- Vera Therapeutics's EBITDA decreased by 118.9% year-over-year, from -$57.11M to -$124.99M.
- What is the long-term trend for Vera Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Vera Therapeutics's EBITDA has grown at a 74.2% compound annual growth rate (CAGR), from -$34.23M to -$315.01M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.